TG Therapeutics: Briumvi's Peak May Be Far Away (Rating Upgrade) (NASDAQ:TGTX)

seekingalpha.com · 2026-08-26

TG Therapeutics raised its Briumvi U.S. net product revenue from $885-$900 million to $890-$905 million. Read why TGTX stock is upgraded to a buy.